Overall survival (OS) was significantly better in lymphoma hosts receiving anti-CD19 CAR T cells, and the benefits of CAR T-cell administration were enlarged in progress free survival (PFS) (Figure 2A). The gene discussed is CD19; the disease is lymphoma.